See more : U.S. Aerospace, Inc. (USAE) Income Statement Analysis – Financial Results
Complete financial analysis of Hexima Limited (HXL.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hexima Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Devon Energy Corporation (0I8W.L) Income Statement Analysis – Financial Results
- Nocturne Acquisition Corporation (MBTCR) Income Statement Analysis – Financial Results
- Acerus Pharmaceuticals Corporation (ASPCF) Income Statement Analysis – Financial Results
- Xstate Resources Limited (XSTLF) Income Statement Analysis – Financial Results
- Globrands Ltd. (GLRS.TA) Income Statement Analysis – Financial Results
Hexima Limited (HXL.AX)
About Hexima Limited
Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company's lead drug candidate is the plant defensin, pezadeftide, which is in phase IIb clinical trials for the treatment of fungal toenail infections in Australia and New Zealand. Hexima Limited was incorporated in 1997 and is based in Preston, Australia.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2010 | 2009 | 2008 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 0.00 | 1.48M | 5.81M | 4.08M | 88.18K | 797.68K | 1.74M | 1.81M | 2.25M | 4.80M | 4.44M | 3.25M | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 11.44K | 141.29K | 147.98K | 265.00K | 259.02K | 516.51K | 537.03K | 567.33K | 868.70K | 984.95K | 626.64K | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 1.47M | 5.67M | 3.93M | -176.81K | 538.66K | 1.22M | 1.27M | 1.69M | 3.93M | 3.46M | 2.63M | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 0.00% | 99.23% | 97.57% | 96.37% | -200.51% | 67.53% | 70.27% | 70.27% | 74.83% | 81.91% | 77.82% | 80.73% | 0.00% | 0.00% | 0.00% |
Research & Development | 0.00 | 883.79K | 11.48M | 7.68M | 4.02M | 4.51M | 397.15K | 327.48K | 5.27M | 4.45M | 4.48M | 4.17M | 4.37M | 9.72M | 2.24M |
General & Administrative | 0.00 | 2.34M | 3.14M | 2.72M | 1.73M | 1.20M | 1.18M | 1.12M | 1.49M | 783.63K | 952.84K | 982.86K | 2.78M | 3.20M | 2.95M |
Selling & Marketing | 0.00 | 52.04K | 350.68K | 109.34K | 126.75K | 392.19K | 43.43K | 40.35K | 63.40K | 318.67K | 231.89K | 238.74K | 478.68K | 477.55K | 389.54K |
SG&A | 1.01M | 2.42M | 3.49M | 2.83M | 1.86M | 1.59M | 1.22M | 1.16M | 1.56M | 1.10M | 1.18M | 1.22M | 3.26M | 3.68M | 3.34M |
Other Expenses | 0.00 | 1.49M | 5.81M | 4.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.14M | 1.05M | 1.16M |
Operating Expenses | 1.01M | 3.31M | 15.72M | 10.99M | 5.88M | 6.10M | 1.62M | 1.49M | 6.82M | 6.15M | 6.11M | 5.87M | 8.43M | 14.40M | 6.60M |
Cost & Expenses | 1.01M | 3.32M | 15.72M | 10.99M | 6.04M | 6.27M | 1.80M | 1.68M | 7.03M | 7.02M | 7.09M | 6.50M | 8.43M | 14.40M | 6.60M |
Interest Income | 40.06K | 38.97K | 1.54K | 1.45K | 2.55K | 10.48K | 21.55K | 17.55K | 42.89K | 134.04K | 222.66K | 394.09K | 1.17M | 2.08M | 2.41M |
Interest Expense | 0.00 | 33.30K | 115.31K | 147.43K | 180.78K | 17.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 13.21K | 11.44K | 141.29K | 147.98K | 162.36K | 172.48K | 182.61K | 194.01K | 205.26K | 210.88K | 228.92K | 238.30K | 135.29K | 81.48K | 29.44K |
EBITDA | -995.54K | -3.08M | -15.21M | -10.34M | -5.19M | -4.84M | 448.28K | 383.44K | -4.41M | -4.13M | -4.56M | -4.93M | -5.98M | -11.19M | -3.00M |
EBITDA Ratio | 0.00% | -222.68% | -168.04% | -161.15% | -6,568.44% | -664.98% | 6.85% | 17.67% | -202.75% | -38.93% | -54.54% | -92.42% | 0.00% | 0.00% | 0.00% |
Operating Income | -1.01M | -3.32M | -9.91M | -6.73M | -5.95M | -5.48M | -63.65K | 125.19K | -4.78M | -2.08M | -2.65M | -3.24M | -8.43M | -14.40M | -6.60M |
Operating Income Ratio | 0.00% | -223.46% | -170.47% | -164.78% | -6,752.55% | -686.61% | -3.66% | 6.93% | -211.85% | -43.32% | -59.70% | -99.75% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 13.20K | 38.05K | -116.05K | 33.49K | 423.29K | 449.37K | 329.32K | 64.25K | 156.53K | -2.33K | 222.66K | 394.09K | 1.71M | 2.08M | 2.41M |
Income Before Tax | -995.55K | -3.10M | -10.02M | -6.87M | -5.53M | -5.03M | 265.67K | 189.44K | -4.62M | -2.08M | -2.43M | -2.85M | -6.12M | -11.28M | -3.03M |
Income Before Tax Ratio | 0.00% | -208.53% | -172.45% | -168.39% | -6,272.55% | -630.27% | 15.29% | 10.49% | -204.91% | -43.37% | -54.68% | -87.63% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | -61.67K | -1.18M | 5.92M | 4.41M | -1.91M | -2.13M | 2.22M | 2.05M | -2.68M | 0.00 | 0.00 | 0.00 | -1.17M | -2.08M | -2.41M |
Net Income | -933.87K | -1.92M | -10.02M | -6.87M | -3.63M | -2.90M | -1.95M | -1.86M | -1.94M | -2.08M | -2.43M | -2.85M | -6.12M | -11.28M | -3.03M |
Net Income Ratio | 0.00% | -129.24% | -172.45% | -168.39% | -4,111.59% | -362.99% | -112.32% | -102.75% | -86.02% | -43.37% | -54.68% | -87.63% | 0.00% | 0.00% | 0.00% |
EPS | -0.01 | -0.01 | -0.07 | -0.06 | -0.03 | -0.04 | -0.03 | -0.03 | -0.05 | -0.05 | -0.06 | -0.07 | -0.08 | -0.14 | -0.04 |
EPS Diluted | -0.01 | -0.01 | -0.07 | -0.06 | -0.03 | -0.04 | -0.03 | -0.03 | -0.05 | -0.05 | -0.06 | -0.07 | -0.08 | -0.14 | -0.04 |
Weighted Avg Shares Out | 167.04M | 167.04M | 152.69M | 111.92M | 130.24M | 65.12M | 64.95M | 64.95M | 40.59M | 40.59M | 40.59M | 40.59M | 79.38M | 78.16M | 67.92M |
Weighted Avg Shares Out (Dil) | 167.04M | 167.04M | 152.69M | 111.92M | 130.24M | 65.12M | 64.94M | 64.94M | 40.59M | 40.59M | 40.59M | 40.59M | 79.38M | 78.16M | 67.92M |
Source: https://incomestatements.info
Category: Stock Reports